If you or a loved one took Tasigna to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and were later diagnosed with atherosclerosis, peripheral arterial disease, circulation issues (heart, brain, legs or arms), or suffered from an amputation, you may be eligible for financial compensation by filing a Tasigna lawsuit.
Tasigna (nilotinib) is an oral chemotherapy drug first approved by the U.S. Food & Drug Administration (FDA) in the fall of 2007. The medication is used to treat a form of cancer known as Philadelphia chromosome-positive chronic myelogenous leukemia, which affects the body’s white blood cells. Tasigna lawyers believe persons and family members of persons who were harmed by Tasigna side effects may be eligible for real compensation by filing a lawsuit.
Regrettably, Tasigna has also been associated with serious negative effects which range from plaque buildup in blood vessels to complications leading within the amputations of legs and feet. Because of this many patient diagnosed using atherosclerosis, peripheral vascular disease, flow problems (heart, brain, arms or legs ), or amputation, have started to document Tasigna suits from the drug’s manufacturer, Novartis.
Philadelphia chromosome-positive chronic myelogenous leukemia is a form of cancer which causes bone marrow to produce a lot of white blood cells that can be frequently damaged or immature.
That is really since the individual’s bone marrow cells possess an abnormal chromosome that may cause an over production of white blood cells. Because white blood cells are your body’s key defense mechanisms, quite a few different problems could originate in Ph+ CML.
As stated by the National Cancer Institute Ph+ CML cases are rather infrequent, having a estimated 8,950 brand new cases in 20 17, leading in only over 1000 deaths. The medication falls to a type of medicine called second generation tyrosine kinase inhibitors (TKIs).
This medication type is called a naturopathic therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic period. TKIs have demonstrated an increased speed of profound molecular reply, together with better premature charge of this disorder compared to previous therapy types for example imatinib.
The advantages and risks, in addition to the long-term ramifications, of Tasigna in contrast with imatinib have never yet been established. By inhibiting such a tyrosine kinases protein, then Tasigna may stop fresh pancreatic cells by growing.
Tasigna (nilotinib), like all cancer drugs, has a long list of common and serious side effects. If you have experienced any of the following while on, or after stopping Tasigna, contact your doctor or oncologist immediately.